Lipid-based nanoformulations in the treatment of neurological disorders

Pharmacology, Toxicology and Pharmaceutical Science

• Solid Lipid Nanoparticle 100%
• Brain Ischemia 33%
• Receptor 33%
• Disease Course 33%
• Central Nervous System Agent 33%
• Claudin 33%
• Receptor-Mediated Endocytosis 33%
• Nerve Cell Degeneration 33%
• Junctional Adhesion Molecule 33%
• Low Density Lipoprotein Receptor 33%
• Nanomedicine 33%
• Systemic Circulation 33%
• Synuclein 33%
• Transcytosis 33%
• Occludin 33%
• Protein Kinase B 33%
• Blood-Brain Barrier 33%
• Apolipoprotein 33%

Medicine and Dentistry

• Apolipoprotein 33%
• Pericyte 33%
• Synuclein 33%